

## DADE BEHRING

DADE BEHRING INC.  
P.O. Box 6101  
Newark, DE 19714

Summary of Safety and Effectiveness Information

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

**Submitter's Name:** Richard M. Vaught  
Dade Behring Inc.  
P.O. Box 6101  
Newark, DE 19714-6101

**Date of Preparation:** December 20, 1999

**Name of Product:** TRNF Flex® Reagent Cartridge

**FDA Classification Name:** Transferrin, Antigen, Antiserum, Control; 82DDG

**Predicate Device:** Beckman Array® Transferrin (TRF) method (K780913; K922273)

**Device Description:** The TRNF Flex® reagent cartridge for the Dimension® clinical chemistry system is a quantitative, turbidimetric assay using endpoint detection, based on the precipitation of transferrin (TRNF) by its polyclonal antibody.


**Intended Use:** The TRNF Flex® reagent cartridge is used in the Dimension® clinical chemistry system to quantitatively measure TRNF in human serum and heparinized plasma.

**Comparison to Predicate Device:**

<u>Item</u>	<u>Dimension® TRNF Flex® Reagent Cartridge</u>	<u>Beckman. TRF method</u>
Sample Type	Serum and plasma	Serum
Methodology	Immunoprecipitation	Immunoprecipitation
Antibody	Rabbit polyclonal	Goat polyclonal
Detection	Bichromatic endpoint (340 and 700 nm) (turbidimetry)	Nephelometry (405 nm)

**Comments on Substantial Equivalence:** Split sample comparison between the TRNF Flex® reagent cartridge method and the Beckman Array® TRF method gave a correlation coefficient of 0.984, slope of 0.90, and an intercept of 7.9 mg/dL when tested with 95 clinical patient samples.

**Conclusion:** The TRNF Flex® reagent cartridge method is substantially equivalent in principle and performance to the Beckman Array® TRF method based on the split sample comparison discussed above.

  
Richard M. Vaught

Regulatory Affairs and Compliance Manager  
Date: December 20, 1999



DEPARTMENT OF HEALTH & HUMAN SERVICES

FEB 4 2000

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Mr. Richard M. Vaught  
Regulatory Affairs and Compliance Manager  
Dade Behring Inc.  
Building 500, Mailbox 514  
P.O. Box 6101  
Newark, Delaware 19714-6101

Re: K994294  
Trade Name: Dimension® TRNF Flex® Reagent Cartridge  
Regulatory Class: II  
Product Code: DDG  
Dated: December 20, 1999  
Received: December 21, 1999

Dear Mr. Vaught:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, flowing style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

Indications For Use Statement

Device Name:

K994294

Dimension® TRNF Flex® Reagent Cartridge

Indications for Use:

The TRNF Flex® reagent cartridge for the Dimension® Clinical Chemistry System is an *in vitro* diagnostic device used to measure by immunochemical techniques the transferrin in human serum and heparinized plasma. Measurement of transferrin levels aids in the diagnosis of malnutrition, acute inflammation, infection, and red blood cell disorders, such as iron deficiency anemia.




Richard M. Vaught  
Regulatory Affairs and Compliance Manager

December 20, 1999

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number

K994294

Prescription Use ☒  
(Per 21 CFR 801.109)

OR

Over-the-counter Use ☐

(Optional format 1-2-96)